NewCardio's Chief Medical Officer to Present NewCardio Studies of Novel Cardiac Safety Biomarkers at Cambridge Healthtech Institute Drug Safety Conference

Dr. Ihor Gussak to Chair Session at Industry Conference

Oct 12, 2010, 08:00 ET from NewCardio, Inc.

SANTA CLARA, Calif., Oct. 12 /PRNewswire-FirstCall/ -- NewCardio, Inc. (OTC Bulletin Board: NWCI), a cardiovascular diagnostic solutions developer, announced today that Dr. Ihor Gussak, MD, PhD, FACC, NewCardio's Vice President and Chief Medical Officer, will join a distinguished roster of speakers, moderators and panelists at the Cambridge Healthtech Institute (CHI) inaugural conference entitled "Mitigating Safety Risks in Early Clinical Development." The conference, which NewCardio will co-sponsor, is scheduled for November 8-9, 2010, at the Crowne Plaza Hotel in Philadelphia.  

At the conference, Dr. Gussak has been invited to chair a scientific session addressing cardiac drug safety, and also will make a 30-min presentation entitled "Novel Three-Dimensional Electrocardiographic and Vectorcardiographic Cardiac Safety Markers in Early Clinical Drug Development."  In his presentation, Dr. Gussak will present data showing that two NewCardio products, QTinno™ and Cardio3KG™, provide an array of novel 3-D electrocardiographic markers that substantially improve detection of drug cardiac safety risks.  

Dr. Ihor Gussak, commented, "I am honored to participate in this important industry conference and discuss the application of NewCardio's platform technology to improve accuracy and enhance value in clinical drug studies.  Our results show that novel cardiac safety markers developed with QTinno and Cardio3KG enable better detection of drug cardiac arrhythmia risk, and may also help to detect drug-induced risk of other adverse cardiac effects such as myocardial infarction, commonly referred to as a heart attack.  This is an excellent opportunity to share our latest developments and discuss the far-reaching potential of our technology with key representatives of drug regulatory agencies and the pharma industry."

CHI is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.  Founded in 1992, CHI strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments.

NewCardio's innovative 3-D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12-lead (12L) ECG. NewCardio's lead product, QTinno, is a software suite that provides automated, comprehensive cardiac safety analysis as defined in the ICH E14 Guidance for Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. The Company believes that QTinno, based on NewCardio's technology and approach, is the industry's most advanced, validated software solution for performing high quality, cost effective automated cardiac safety analysis in drug development.  NewCardio is developing the Cardio3KG solution for urgent care diagnosis of serious cardiac conditions, including acute myocardial infarction and other acute coronary syndromes.  In clinical studies to date, Cardio3KG has shown substantially improved diagnostic accuracy relative to the standard 12L ECG, particularly in the most diagnostically challenging patients (such as those with diabetes and electrical conduction abnormalities).  Accordingly, the Company believes that its innovative Cardio3KG solution will substantially improve diagnostic speed and accuracy in life-threatening cardiac conditions, and will thereby improve clinical outcomes for a broad range of cardiac patients.  The Cardio3KG is not currently marketed; the Company intends to file an application for 510(k) notification with the FDA during 2011.

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12L ECG.  NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect.  NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link:

Investor Contact:

Hayden IR

Jeff Stanlis, Partner

(602) 476-1821

SOURCE NewCardio, Inc.